LUMO - Lumos Pharma GAAP EPS of -$0.86 beats by $0.15 revenue of $0.49M
- Lumos Pharma press release ( NASDAQ: LUMO ): Q3 GAAP EPS of -$0.86 beats by $0.15 .
- Revenue of $0.49M.
- Lumos Pharma ended the quarter on September 30, 2022 with cash and cash equivalents totaling $73.7 million compared to $94.8 million on December 31, 2021.
For further details see:
Lumos Pharma GAAP EPS of -$0.86 beats by $0.15, revenue of $0.49M